APA (7th ed.) Citation

MJ, P., S, S., V, N., MT, K., R, N., & EM, G. (2025). Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France. PharmacoEconomics, 43(8), 937. https://doi.org/10.1007/s40273-025-01501-3

Chicago Style (17th ed.) Citation

MJ, Pilz, Seyringer S, Nerich V, King MT, Norman R, and Gamper EM. "Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D Against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France." PharmacoEconomics 43, no. 8 (2025): 937. https://doi.org/10.1007/s40273-025-01501-3.

MLA (9th ed.) Citation

MJ, Pilz, et al. "Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D Against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France." PharmacoEconomics, vol. 43, no. 8, 2025, p. 937, https://doi.org/10.1007/s40273-025-01501-3.